How 23andMe Went From 6B Valuation to Penny Stock WSJ What Went Wrong

The DNA testing company 23AndMe and its founder Anne Wojcicki aimed to revolutionize healthcare, bringing genetic testing to the home with just a drop of saliva. However, challenges with the business model and persistent concerns about consumer data privacy caused the once $6 billion valuation to plummet to near $0, leading to threats of delisting from the Nasdaq.

The WSJ explains what happened to Wojcicki's biotechnology business.

Chapters:
0:00 At-Home DNA Testing
0:49 The Rise of 23andMe
2:18 The Turning Point
4:03 The Fall of 23andMe
5:23 What Happens Next?

What Went Wrong explores the challenging conditions and decisions that led to a company's downfall.